apps

HitLab awards grand prize to MedComms Agency, Lighthouse, for its voice-activated diabetes app

Lighthouse_Logo2017 Hitlab Innovators Summit named Lighthouse as the winner of its World Cup Challenge, which focuses on using voice-activated technology aimed at improving healthcare access, delivery, and outcomes. Lighthouse received $50,000 for its voice-activated application, designed to provide more accessible and engaging care for diabetes patients.

“Lighthouse really honed in on an important gap — how can we expand patient support between appointments?” said Amy West, Novo Nordisk’s Senior Director of Patient Marketing and Digital Health Innovation, and a judge of the challenge. “The ability to address this issue, coupled with Lighthouse’s seamless integration into the lives of patients, are the core reasons why it was selected as this year’s grand prize winner.”

“Lighthouse helps patients close that gap, build great habits, and support their broader care team in delivering the best care,” said Lighthouse CEO, Dave Vockell.

Hitlab received a total of 146 applications from 15 different countries this year. Finalists then had to make their pitches to a panel of judges at the three-day event held in New York City.

Judges evaluated the pitches according to the following criteria:

    • Impact
    • Innovation
    • Sustainability

Finalists included cloud-based app My Diabetes Coach, developed by Macadamian; virtual nutrition assistant T2D2; nutrition-tracking smart placemat Palette; and Proof, which supports patient/provider relationships.

Novo Nordisk, which sponsored the Innovators Summit, has yet to determine whether it will partner with any of finalists, said West. “Novo Nordisk will continue its foray into digital health by exploring many different opportunities that align with our business strategy.”

The company does, however, expect to embrace voice technology, according to David Moore, Novo’s Commercial SVP. “We think about the fact that everyone will have a smartphone in the not-too-distant future. It’s a disruptive technology,” he said.

Diabetes is a condition which could greatly benefit from more pharma/tech collaboration, Moore added. “If you’re an employer, you’re looking for more productivity. If you’re a patient, you’re looking for more information and more personalized care. This integration in a digital platform around diabetes has the potential for a large impact.”

Source: MM&M

News